BioMarin 10-Q Details $122.8M Q3 Loss, $4.2B Debt Load After Amicus Deal
BMRN is trading near its 52-week low of $49.259 (13% above the low) on elevated volume (2.0× avg).
Summary
BioMarin's Q3 10-Q confirms the $1,024.6M revenue quarter but details a $122.8M net loss, cash down to $736.0M, and $4.2B of debt after the Amicus and Alesta deals.
Key Events · Earnings and Guidance · BMRN
-
Q3 Revenue Jumps 32% to $1,024.6M
Total revenues rose to $1,024.6M from $776.1M a year earlier, with acquired Amicus products GALAFOLD ($151.8M) and POMBILITI + OPFOLDA ($48.6M) contributing $200.4M.
-
Quarter Swings to $122.8M Net Loss
Diluted EPS was -$0.63, driven by a $287.7M acquired IPR&D charge from Alesta and $99.5M of intangible amortization; nine-month net income was only $27.5M versus $395.5M in 2025.
-
Cash Falls to $736.0M, Debt Hits $4.2B
Cash and investments dropped from $2,052.8M at December 31, 2025 to $736.0M, while total debt principal reached $4.2B and Q3 interest expense was $55.6M; the $600.0M revolver remains undrawn.
-
Amicus Adds $336.4M Revenue, $239.4M Loss
Since the April 27, 2026 close, Amicus contributed $336.4M of revenue and a $239.4M net loss, including $82.6M of integration severance within $113.6M of nine-month restructuring charges.
Analysis · BMRN · Life Sciences
The headline Q3 numbers were already out on November 2, but the full 10-Q shows what the acquisition-heavy year has done to the balance sheet: cash and investments fell to $736.0M from $2,052.8M at year-end 2025, while total debt principal jumped to $4.2B and quarterly interest expense reached $55.6M. Revenue growth is real — Q3 total revenues of $1,024.6M versus $776.1M a year ago, with Amicus products GALAFOLD and POMBILITI + OPFOLDA adding $200.4M — but the quarter still produced a $122.8M net loss driven by a $287.7M acquired IPR&D charge from Alesta and $99.5M of intangible amortization. Nine-month operating cash flow of $577.0M is down from $728.4M, so the company is now servicing a much larger debt stack with less liquidity cushion. Management states cash plus product cash flow covers at least the next 12 months, and the $600.0M revolver is undrawn, which is the key offset. The October GC Biopharma/Hanmi BMN 450 license adds another $70.0M IPR&D charge in Q4, so the GAAP loss pattern continues near term.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMRN was trading at $55.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8B. The 52-week trading range was $49.26 to $70.98. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.